BD Phoenix™ Automated Microbiology System

The BD Phoenix Automated Microbiology System is an in vitro diagnostic device for rapid identification and antimicrobial susceptibility testing (AST) of clinically significant bacteria from pure cultures. It determines minimal inhibitory concentrations (MIC) for Gram-positive and Gram-negative bacteria, reporting results in under 16 hours with categorical interpretations (susceptible, intermediate, resistant). The device can operate standalone or connected to BD Synapsys informatics software, which integrates laboratory workflows and provides expert rule-based guidance through the BDXpert software module.

The device is a broth-based microdilution system using a redox colorimetric indicator to detect organism growth in the presence of serial two-fold antibiotic dilutions. The key difference from the predicate (K131331) is connectivity: the predicate connects to EpiCenter, while this submission adds Synapsys connectivity with enhanced BDXpert functionality including Disease Specific Breakpoint Interpretation, Source Specific Breakpoint Interpretation, Zone Breakpoint Interpretation, and Dose Dependent Interpretations. All other core characteristics—methodology, algorithms, incubation time, and result reporting—remain identical.

Performance testing was conducted per ISO 13485:2016 (quality management), IEC 62304:2015 (medical device software lifecycle), ISO 14971:2019 (risk management), and FDA guidance for Device Software Functions (issued June 14, 2023). Software verification and validation activities were performed to demonstrate intended performance.

Substantial equivalence is established because the device uses the identical broth microdilution methodology, redox detection technology, ID and AST algorithms, inoculation methods, and result reporting as the predicate K131331. The sole change is substituting Synapsys connectivity for EpiCenter connectivity and adding advanced built-in breakpoint interpretation functionality; these are software enhancements that do not alter the fundamental detection principle, clinical intended use, or analytical methodology. Since the predicate's core technology and performance remain unchanged and the Synapsys connection is merely an alternative software integration pathway with added analytical features, substantial equivalence is maintained.